A novel cytokine, designated Apo-2 ligand, which induces mammalian cancer
cell apoptosis is provided. The Apo-2 ligand is believed to be a member of
the TNF cytokine family. Compositions including Apo-2 ligand chimeras,
nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are
also provided. Methods of using Apo-2 ligand to induce apoptosis and to
treat pathological conditions such as cancer, are further provided.
